No Data
No Data
Raily aesmed (02135.HK) issued a warning about the expected net loss of 2 million yuan in the first half of the year.
On August 7th, Gelonhui reported that the Board of Directors of Raily Aesmed (02135.HK) anticipates that the Group will record: (i) revenue of approximately RMB 0.117 billion for the six months ending on June 30, 2024; and (ii) a loss attributable to owners of the parent company of approximately RMB 2 million for the six months ending on June 30, 2024 (for the 6 months ending on June 30, 2023, the loss attributable to owners of the parent company was approximately RMB 2 million). The Board of Directors believes that the continuous losses are mainly due to the following reasons: (a) in order to accelerate the research and development and production of the group's medical instruments products, the group has increased indirect investment in the company.
Express News | Raily Aesthetic Medicine International Sees Revenue of RMB117 Mln for Hy
Express News | Raily Aesthetic Medicine International Sees Loss Attributable RMB2 Mln for Six Months
BOC International: Continued prosperity of upstream medical beauty manufacturers opens up space for external expansion.
According to the research reports released by BOC International, the performance of leading medical and aesthetic companies is still maintaining good growth, and the average product price has not shown any price reduction pressure. The constantly enriched product matrix is expected to bring growth in the future.
Raily Aesthetic Medicine International Holdings Limited's (HKG:2135) 53% Dip In Price Shows Sentiment Is Matching Revenues
Ruili Medical & Aesthetic (02135.HK) issued and allotted approximately 139 million new shares under the share offering
On April 25, Ge Longhui (02135.HK) issued an announcement. On April 25, 2024, approximately 139 million new shares will be issued and allocated in accordance with the share offering.
No Data